Date: 2015-11-20
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Galapagos (Belgium) Servier (France)
Product: GLPG1972
Action mechanism:
Disease: osteoarthritis
Therapeutic area: Rheumatic diseases - Inflammatory diseases – Bone diseases
Country: Belgium
Trial details:
Latest
news: * On November 20, 2015, Galapagos announced that GLPG1972, a first-in-class candidate drug aiming at treating osteoarthritis, has been dosed in a Phase 1 First-in-Human study. GLPG1972 has a novel mode of action discovered by Galapagos under its collaboration agreement with Servier, and has potential application in osteoarthritis. Galapagos will receive a €3.5 million milestone payment from Servier for this achievement. The aim of the Phase 1 study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral single and multiple ascending doses of GLPG1972. The randomized, double-blind, placebo-controlled, single center study is being conducted in at least 40 healthy volunteers in Belgium. In the first part of the study, single ascending doses will be evaluated. In the second part, the new compound will be administered daily for 14 days in multiple ascending doses. Topline results are expected in the second quarter of 2016.
